Clinical Significance of Serum BFP and Various Tumor Markers in Primary Lung Cancer
To investigate the clinical significance of BFP (basic fetoprotein) in lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markers such as CEA, SLX, CA 19-9, CA 125, TPA, SCC, and NSE w...
Gespeichert in:
| Veröffentlicht in: | Haigan 1994/02/20, Vol.34(1), pp.37-45 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 45 |
|---|---|
| container_issue | 1 |
| container_start_page | 37 |
| container_title | Haigan |
| container_volume | 34 |
| creator | Horiguchi, Takahiko Tachikawa, Souichi Tamaki, Seisi Kato, Makoto Doi, Masashi Hanazono, Kimihiko Takeuchi, Noriyuki Munekata, Eizi Hirabuki, Kouichi Handa, Misuzu |
| description | To investigate the clinical significance of BFP (basic fetoprotein) in lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markers such as CEA, SLX, CA 19-9, CA 125, TPA, SCC, and NSE were also measured. In 58% of the patients with primary lung cancer, BFP was positive. This rate was higher than that of CEA and SLX, but lower than that of TPA. Histologically, BFP tended to occur more frequently in small cell carcinoma and large cell carcinoma. CEA and SLX showed high specificity in adenocarcinoma, and SCC and NSE showed high specificity in squamous cell carcinoma and small cell carcinoma, respectively. BFP levels tended to be higher in the advanced stages of disease and the change of BFP levels was related to chemotherapeutic response. However this tendency was not observed in patients who did not respond to chemotherapy; this was particularly pronounced in small cell carcinoma. In the study of various tumor markers, a correlation was observed only between BFP and NSE, which suggests that these two tumor markers are valuable in combination assay. In conclusion, measurement of BFP is a useful method of monitoring the effectiveness of treatment in primary lung cancer. |
| doi_str_mv | 10.2482/haigan.34.37 |
| format | Article |
| fullrecord | <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2482_haigan_34_37</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_haigan1960_34_1_34_1_37_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2627-cad8f8ca3aba34f8db5539c93f79dc10fe0c4f261385942003117180272702d63</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EEqVw4wH8AKTY3sQ_R4jaglREpRaukevYqUvqILs58Pa0StXL7kr7zWg0CD1SMmG5ZM9b7RsdJpBPQFyhEYVcZkopdo1GBCTPFGfyFt2ltCOEs4LDCK3K1gdvdItXvgneHc9gLO4cXtnY7_HrbIl1qPG3jr7rE173-y7iDx1_bEzYB7yMfq_jH170ocHlSRzv0Y3TbbIP5z1GX7PpunzLFp_z9_JlkRnGmciMrqWTRoPeaMidrDdFAcoocELVhhJnickd4xRkoXJGCFAqqCRMMEFYzWGMngZfE7uUonXV7xCmoqQ6FVINhVSQVyCO-HTAd-mgG3uBdTx409ozTBUnJwE9D3H5m62OlQ3wDwzebIc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical Significance of Serum BFP and Various Tumor Markers in Primary Lung Cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Horiguchi, Takahiko ; Tachikawa, Souichi ; Tamaki, Seisi ; Kato, Makoto ; Doi, Masashi ; Hanazono, Kimihiko ; Takeuchi, Noriyuki ; Munekata, Eizi ; Hirabuki, Kouichi ; Handa, Misuzu</creator><creatorcontrib>Horiguchi, Takahiko ; Tachikawa, Souichi ; Tamaki, Seisi ; Kato, Makoto ; Doi, Masashi ; Hanazono, Kimihiko ; Takeuchi, Noriyuki ; Munekata, Eizi ; Hirabuki, Kouichi ; Handa, Misuzu</creatorcontrib><description>To investigate the clinical significance of BFP (basic fetoprotein) in lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markers such as CEA, SLX, CA 19-9, CA 125, TPA, SCC, and NSE were also measured. In 58% of the patients with primary lung cancer, BFP was positive. This rate was higher than that of CEA and SLX, but lower than that of TPA. Histologically, BFP tended to occur more frequently in small cell carcinoma and large cell carcinoma. CEA and SLX showed high specificity in adenocarcinoma, and SCC and NSE showed high specificity in squamous cell carcinoma and small cell carcinoma, respectively. BFP levels tended to be higher in the advanced stages of disease and the change of BFP levels was related to chemotherapeutic response. However this tendency was not observed in patients who did not respond to chemotherapy; this was particularly pronounced in small cell carcinoma. In the study of various tumor markers, a correlation was observed only between BFP and NSE, which suggests that these two tumor markers are valuable in combination assay. In conclusion, measurement of BFP is a useful method of monitoring the effectiveness of treatment in primary lung cancer.</description><identifier>ISSN: 0386-9628</identifier><identifier>EISSN: 1348-9992</identifier><identifier>DOI: 10.2482/haigan.34.37</identifier><language>eng ; jpn</language><publisher>The Japan Lung Cancer Society</publisher><subject>BFP ; Lung cancer ; Tumor markers</subject><ispartof>Haigan, 1994/02/20, Vol.34(1), pp.37-45</ispartof><rights>The Japan Lung Cancer Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids></links><search><creatorcontrib>Horiguchi, Takahiko</creatorcontrib><creatorcontrib>Tachikawa, Souichi</creatorcontrib><creatorcontrib>Tamaki, Seisi</creatorcontrib><creatorcontrib>Kato, Makoto</creatorcontrib><creatorcontrib>Doi, Masashi</creatorcontrib><creatorcontrib>Hanazono, Kimihiko</creatorcontrib><creatorcontrib>Takeuchi, Noriyuki</creatorcontrib><creatorcontrib>Munekata, Eizi</creatorcontrib><creatorcontrib>Hirabuki, Kouichi</creatorcontrib><creatorcontrib>Handa, Misuzu</creatorcontrib><title>Clinical Significance of Serum BFP and Various Tumor Markers in Primary Lung Cancer</title><title>Haigan</title><addtitle>JJLC</addtitle><description>To investigate the clinical significance of BFP (basic fetoprotein) in lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markers such as CEA, SLX, CA 19-9, CA 125, TPA, SCC, and NSE were also measured. In 58% of the patients with primary lung cancer, BFP was positive. This rate was higher than that of CEA and SLX, but lower than that of TPA. Histologically, BFP tended to occur more frequently in small cell carcinoma and large cell carcinoma. CEA and SLX showed high specificity in adenocarcinoma, and SCC and NSE showed high specificity in squamous cell carcinoma and small cell carcinoma, respectively. BFP levels tended to be higher in the advanced stages of disease and the change of BFP levels was related to chemotherapeutic response. However this tendency was not observed in patients who did not respond to chemotherapy; this was particularly pronounced in small cell carcinoma. In the study of various tumor markers, a correlation was observed only between BFP and NSE, which suggests that these two tumor markers are valuable in combination assay. In conclusion, measurement of BFP is a useful method of monitoring the effectiveness of treatment in primary lung cancer.</description><subject>BFP</subject><subject>Lung cancer</subject><subject>Tumor markers</subject><issn>0386-9628</issn><issn>1348-9992</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNo9kM1OwzAQhC0EEqVw4wH8AKTY3sQ_R4jaglREpRaukevYqUvqILs58Pa0StXL7kr7zWg0CD1SMmG5ZM9b7RsdJpBPQFyhEYVcZkopdo1GBCTPFGfyFt2ltCOEs4LDCK3K1gdvdItXvgneHc9gLO4cXtnY7_HrbIl1qPG3jr7rE173-y7iDx1_bEzYB7yMfq_jH170ocHlSRzv0Y3TbbIP5z1GX7PpunzLFp_z9_JlkRnGmciMrqWTRoPeaMidrDdFAcoocELVhhJnickd4xRkoXJGCFAqqCRMMEFYzWGMngZfE7uUonXV7xCmoqQ6FVINhVSQVyCO-HTAd-mgG3uBdTx409ozTBUnJwE9D3H5m62OlQ3wDwzebIc</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>Horiguchi, Takahiko</creator><creator>Tachikawa, Souichi</creator><creator>Tamaki, Seisi</creator><creator>Kato, Makoto</creator><creator>Doi, Masashi</creator><creator>Hanazono, Kimihiko</creator><creator>Takeuchi, Noriyuki</creator><creator>Munekata, Eizi</creator><creator>Hirabuki, Kouichi</creator><creator>Handa, Misuzu</creator><general>The Japan Lung Cancer Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1994</creationdate><title>Clinical Significance of Serum BFP and Various Tumor Markers in Primary Lung Cancer</title><author>Horiguchi, Takahiko ; Tachikawa, Souichi ; Tamaki, Seisi ; Kato, Makoto ; Doi, Masashi ; Hanazono, Kimihiko ; Takeuchi, Noriyuki ; Munekata, Eizi ; Hirabuki, Kouichi ; Handa, Misuzu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2627-cad8f8ca3aba34f8db5539c93f79dc10fe0c4f261385942003117180272702d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>1994</creationdate><topic>BFP</topic><topic>Lung cancer</topic><topic>Tumor markers</topic><toplevel>online_resources</toplevel><creatorcontrib>Horiguchi, Takahiko</creatorcontrib><creatorcontrib>Tachikawa, Souichi</creatorcontrib><creatorcontrib>Tamaki, Seisi</creatorcontrib><creatorcontrib>Kato, Makoto</creatorcontrib><creatorcontrib>Doi, Masashi</creatorcontrib><creatorcontrib>Hanazono, Kimihiko</creatorcontrib><creatorcontrib>Takeuchi, Noriyuki</creatorcontrib><creatorcontrib>Munekata, Eizi</creatorcontrib><creatorcontrib>Hirabuki, Kouichi</creatorcontrib><creatorcontrib>Handa, Misuzu</creatorcontrib><collection>CrossRef</collection><jtitle>Haigan</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horiguchi, Takahiko</au><au>Tachikawa, Souichi</au><au>Tamaki, Seisi</au><au>Kato, Makoto</au><au>Doi, Masashi</au><au>Hanazono, Kimihiko</au><au>Takeuchi, Noriyuki</au><au>Munekata, Eizi</au><au>Hirabuki, Kouichi</au><au>Handa, Misuzu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Significance of Serum BFP and Various Tumor Markers in Primary Lung Cancer</atitle><jtitle>Haigan</jtitle><addtitle>JJLC</addtitle><date>1994</date><risdate>1994</risdate><volume>34</volume><issue>1</issue><spage>37</spage><epage>45</epage><pages>37-45</pages><issn>0386-9628</issn><eissn>1348-9992</eissn><abstract>To investigate the clinical significance of BFP (basic fetoprotein) in lung cancer, serum BFP was measured in 50 patients with primary lung cancer and 40 patients with other non-malignant pulmonary diseases. For comparison, various tumor markers such as CEA, SLX, CA 19-9, CA 125, TPA, SCC, and NSE were also measured. In 58% of the patients with primary lung cancer, BFP was positive. This rate was higher than that of CEA and SLX, but lower than that of TPA. Histologically, BFP tended to occur more frequently in small cell carcinoma and large cell carcinoma. CEA and SLX showed high specificity in adenocarcinoma, and SCC and NSE showed high specificity in squamous cell carcinoma and small cell carcinoma, respectively. BFP levels tended to be higher in the advanced stages of disease and the change of BFP levels was related to chemotherapeutic response. However this tendency was not observed in patients who did not respond to chemotherapy; this was particularly pronounced in small cell carcinoma. In the study of various tumor markers, a correlation was observed only between BFP and NSE, which suggests that these two tumor markers are valuable in combination assay. In conclusion, measurement of BFP is a useful method of monitoring the effectiveness of treatment in primary lung cancer.</abstract><pub>The Japan Lung Cancer Society</pub><doi>10.2482/haigan.34.37</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0386-9628 |
| ispartof | Haigan, 1994/02/20, Vol.34(1), pp.37-45 |
| issn | 0386-9628 1348-9992 |
| language | eng ; jpn |
| recordid | cdi_crossref_primary_10_2482_haigan_34_37 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | BFP Lung cancer Tumor markers |
| title | Clinical Significance of Serum BFP and Various Tumor Markers in Primary Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T03%3A09%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Significance%20of%20Serum%20BFP%20and%20Various%20Tumor%20Markers%20in%20Primary%20Lung%20Cancer&rft.jtitle=Haigan&rft.au=Horiguchi,%20Takahiko&rft.date=1994&rft.volume=34&rft.issue=1&rft.spage=37&rft.epage=45&rft.pages=37-45&rft.issn=0386-9628&rft.eissn=1348-9992&rft_id=info:doi/10.2482/haigan.34.37&rft_dat=%3Cjstage_cross%3Earticle_haigan1960_34_1_34_1_37_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |